Baidu
map

JACC:房颤的发生率与心血管事件、心力衰竭、死亡相关

2015-08-25 MedSci MedSci原创

在治疗房颤(AF)相关的疾病方面已经做出了重要改善,如高血压,心肌梗塞和心脏衰竭。发病率和风险因素可能会随着人们年龄和生活方式的改变而改变。目前,房颤的风险只能部分地解释,可能是因为旧的队列和当代人群之间的差异。本研究探讨了荷兰的现代人群房颤的发病率,相关的合并症以及AF与心血管结果联系。PREVEND研究(肾和血管终末期疾病的预防)中8,265名参与者的AF事件是由医院和研究的心电图确定的,该研

在治疗房颤(AF)相关的疾病方面已经做出了重要改善,如高血压、心肌梗塞和心脏衰竭。发病率和风险因素可能会随着人们年龄和生活方式的改变而改变。目前,房颤的风险只能部分地解释,可能是因为旧的队列和当代人群之间的差异。

本研究探讨了荷兰的现代人群房颤的发病率,相关的合并症以及AF与心血管结果联系。

PREVEND研究(肾和血管终末期疾病的预防)中8,265名参与者的AF事件是由医院和研究的心电图确定的,该研究在荷兰格罗宁根进行。

在9.7±2.3年的随访过程中,265名参与者发生了房颤,总的AF发生率为每1000人年3.3例。年龄的增长,男性,抗高血压药物的使用,较高的身体质量指数,以前的心肌梗死卒中史均与AF相关。多因素调整后,AF与心血管事件(危险比[HR],2.24;95%可信区间[Cl]:1.06-4.75,P=0.035),心脏衰竭减少或保持射血分数(HR:4.52;95%Cl:2.02-10.09,P<0.001),全因死亡率(HR:3.02;95%Cl:1.73-5.27;p<0.001)相关。

房颤在本队列的发生率与以前的研究显示的数据具有可比性。肥胖已经成为AF发生的主要危险因素。虽然在本研究中总体心血管事件发生率较低,但本研究证实,房颤事件与这些事件是有联系的。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1853396, encodeId=4993185339609, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Nov 18 07:36:00 CST 2015, time=2015-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826283, encodeId=6766182628366, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Dec 03 03:36:00 CST 2015, time=2015-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643368, encodeId=7de71643368f1, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Oct 11 23:36:00 CST 2015, time=2015-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325089, encodeId=7c76132508960, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 27 08:36:00 CST 2015, time=2015-08-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1853396, encodeId=4993185339609, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Nov 18 07:36:00 CST 2015, time=2015-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826283, encodeId=6766182628366, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Dec 03 03:36:00 CST 2015, time=2015-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643368, encodeId=7de71643368f1, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Oct 11 23:36:00 CST 2015, time=2015-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325089, encodeId=7c76132508960, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 27 08:36:00 CST 2015, time=2015-08-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1853396, encodeId=4993185339609, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Nov 18 07:36:00 CST 2015, time=2015-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826283, encodeId=6766182628366, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Dec 03 03:36:00 CST 2015, time=2015-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643368, encodeId=7de71643368f1, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Oct 11 23:36:00 CST 2015, time=2015-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325089, encodeId=7c76132508960, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 27 08:36:00 CST 2015, time=2015-08-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1853396, encodeId=4993185339609, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Nov 18 07:36:00 CST 2015, time=2015-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826283, encodeId=6766182628366, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Dec 03 03:36:00 CST 2015, time=2015-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643368, encodeId=7de71643368f1, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Oct 11 23:36:00 CST 2015, time=2015-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325089, encodeId=7c76132508960, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 27 08:36:00 CST 2015, time=2015-08-27, status=1, ipAttribution=)]

相关资讯

NEJM:房颤患者的围手术期桥接抗凝治疗

背景:对于需要中断华法林治疗,选择其他治疗方法或其他侵入性操作的房颤患者来说,桥接抗凝治疗是否是必要的目前还不清楚。研究人员假设,放弃桥接抗凝治疗将劣于对于预防动脉围手术期血栓栓塞的低分子量肝素桥接治疗,并对于大出血来说将优于桥接治疗。    方法:研究人员进行了一项随机,双盲,安慰剂对照试验,围手术期华法林治疗中断后,患者被随机分配接受低分子量肝素桥接抗凝治疗(每千

马长生:房颤抗凝治疗适应证新认识

国家心血管病临床医学研究中心、首都医科大学北京安贞医院马长生教授谈房颤抗凝治疗适应证新认识2015年7月31日至8月2日,由中国生物医学工程学会心律分会

起搏器后房颤累积发生率超30%,如何预防有技巧

心脏起搏是目前治疗症状性心动过缓唯一有效的治疗,但植入起搏器后房颤的累积发生率高达30%~40%,显著高于无起搏器植入的普通人群。那么如何降低做好起搏器术后房颤的预防和治疗?阜外心血管医院姚焰教授和樊晓寒博士就此谈了以下几点。 对所有植入起搏器的患者,预防起搏器术后房颤需根据个体病情特点选择尽可能生理的起搏模式和程控间期,最大化起搏的益处,最小化起

JACC:地高辛的使用和房颤患者的死亡预后无关

    背景  虽然地高辛长期用于治疗心房颤动(AF)和心力衰竭(HF),但其安全性仍有争议。    意义  本研究旨在描述通过HF的存在或不存在被分层的房颤患者在一段时间内使用地高辛被,来表征地高辛的使用和起始的预测因子,以及和地高辛使用相关的预后。    方法  在2010年6月至2011年8月期间,地高

JACC:老年房颤患者急性心肌梗死的三联疗法的应用及疗效

    抗血栓治疗对于经皮冠状动脉介入治疗(PCI)治疗的风险较高的心房颤动(AF)老年患者的急性心肌梗死(MI)效果仍不清楚。    这项研究旨在确定适当的抗血栓治疗方法治疗通过PCI治疗房颤的急性MI患者。    研究人员对4,959例≥65岁的急性MI和AF并接受冠状动脉支架置入术(急性冠脉综合治疗及干预结果网络登记处)患者进行了研

Baidu
map
Baidu
map
Baidu
map